Clinical Trial

Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus

Study acronym: OxyTUTION
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This randomized, placebo-controlled, double-blind trial aims to investigate intranasal OXT as a novel therapeutical option in central diabetes insipidus (cDI) to improve psychological symptoms and socio-emotional functioning. Optionally, patients can present for additional assessments in sub-studies: * fMRI sub-study at day 14 (± 2 days) (one additional visit) * Social-stress sub-study at day 14 (± 2 days) (one additional visit)
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-09-06; most recent amendment 2026-05-05.
Status change: Not Yet Recruiting → Recruiting 2024-01-10
Trial Details
NCT Number NCT06036004
Lead Sponsor University Hospital, Basel, Switzerland
Conditions Central Diabetes Insipidus (cDI)
Enrollment 112 participants
Start Date 2024-01-08
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-06